Oncology Speed Read Video overview 

The latest developments in BRAF-mutant and MSI-H mCRC

Expert insights on recent clinical and real-world data

Prof. Chiara Cremolini

Prof. Chiara Cremolini
Publication Date

Jul 2025

info Summary and next episodes download Downloadable resources

Prof. Chiara Cremolini reviews the latest clinical and real-world data in the treatment of BRAF-mutant and MSI-H metastatic colorectal cancer (mCRC), with a particular focus on the following two studies: 

  • BREAKWATER: First-line encorafenib + cetuximab + mFOLFOX6 vs standard of care in BRAFV600E-mutant mCRC 
  • CheckMate 8HW: Nivolumab + ipilimumab vs chemotherapy or nivolumab monotherapy for MSI-H/dMMR mCRC 

Watch the short video for a summary of Professor Cremolini’s perspectives.  Download the slide deck for more details on the data. 

  • Understand clinical trial data and real-world evidence of therapies for the treatment of BRAFV600E-mutant and MSI-H mCRC and relevant patient subgroups 
  • Recognise the appropriate sequencing of therapies for the treatment of BRAFV600E-mutant and MSI-H mCRC across the patient journey to ensure optimal outcomes 

Dr Chiara Cremolini is a Medical Oncologist at Santa Chiara University Hospital in Pisa, Italy. Chiara completed her M.D. Degree in 2008, and gained an M.Sc. in Clinical Trials in 2011, and the Specialty in Medical Oncology in 2014 at the University of Pisa. She is mainly committed to the clinical management of patients affected by gastrointestinal malignancies and is involved in clinical and translational research projects in the field of colorectal oncology. She actively contributes to clinical trials by the cooperative Gruppo Oncologico Nord Ovest (GONO) group and is interested in the identification of molecular predictors of benefit from systemic treatments. Chiara is co-author of about 60 peer-reviewed papers and received merit awards at the following meetings: American Society of Clinical Oncology (ASCO) 2010, 2012−2015; European Society for Medical Oncology (ESMO) 2011 and 2014; European CanCer Organisation (ECCO) 2013.

Prof. Chiara Cremolini has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grants for research projects:

Bayer, Merck, Nordic Pharma, Pierre Fabre, Roche, Servier, Takeda, Tempus, 
pdf Download slides - PDF clock
pdf Download slides - PPTX clock

Prof. Chiara Cremolini reviews the latest clinical and real-world data in the treatment of BRAF-mutant and MSI-H metastatic colorectal cancer (mCRC), with a particular focus on the following two studies: 

  • BREAKWATER: First-line encorafenib + cetuximab + mFOLFOX6 vs standard of care in BRAFV600E-mutant mCRC 
  • CheckMate 8HW: Nivolumab + ipilimumab vs chemotherapy or nivolumab monotherapy for MSI-H/dMMR mCRC 

Watch the short video for a summary of Professor Cremolini’s perspectives.  Download the slide deck for more details on the data. 

  • Understand clinical trial data and real-world evidence of therapies for the treatment of BRAFV600E-mutant and MSI-H mCRC and relevant patient subgroups 
  • Recognise the appropriate sequencing of therapies for the treatment of BRAFV600E-mutant and MSI-H mCRC across the patient journey to ensure optimal outcomes 

Dr Chiara Cremolini is a Medical Oncologist at Santa Chiara University Hospital in Pisa, Italy. Chiara completed her M.D. Degree in 2008, and gained an M.Sc. in Clinical Trials in 2011, and the Specialty in Medical Oncology in 2014 at the University of Pisa. She is mainly committed to the clinical management of patients affected by gastrointestinal malignancies and is involved in clinical and translational research projects in the field of colorectal oncology. She actively contributes to clinical trials by the cooperative Gruppo Oncologico Nord Ovest (GONO) group and is interested in the identification of molecular predictors of benefit from systemic treatments. Chiara is co-author of about 60 peer-reviewed papers and received merit awards at the following meetings: American Society of Clinical Oncology (ASCO) 2010, 2012−2015; European Society for Medical Oncology (ESMO) 2011 and 2014; European CanCer Organisation (ECCO) 2013.

Prof. Chiara Cremolini has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grants for research projects:

Bayer, Merck, Nordic Pharma, Pierre Fabre, Roche, Servier, Takeda, Tempus, 
pdf Download slides - PDF clock
pdf Download slides - PPTX clock
Programme summary
Watch the video now
Share this programme
x-twitter
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
Supporter Acknowledgement
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe, Pierre Fabre Laboratories, Amgen and AstraZeneca US.  

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts
Brought to you by
GI NURSES CONNECT

GI NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved
Programme summary
Share this programme
x-twitter
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
Supporter Acknowledgement
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe, Pierre Fabre Laboratories, Amgen and AstraZeneca US.  

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts
Brought to you by
GI NURSES CONNECT

GI NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology 
Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

A novel therapeutic framework 

Experts
Dr Komal Jhaveri, Oncology Brothers (Moderators)
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education
BREAST CANCER CONNECT PRECISION ONCOLOGY CONNECT
Educational programme supported by an Independent Educational Grant from AstraZeneca 
patient-support Patient Support

Episode

2

of 2

episode
Oncology Endocrinology Rare diseases 
Thriving beyond an EP-NEC diagnosis

Perspectives on treatment and care 

Experts
Jessica Thomas
Endorsed by
NET-Research-Foundation Minkhas mission
  • clock 4 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education
NET CONNECT
Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
patient-support Patient Support

Episode

1

of 2

episode
Oncology Endocrinology Rare diseases 
Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC)

Insights for patients and care partners 

Experts
Meredith Cummins
Endorsed by
INCA
NeuroEndocrine Cancer Australia Neuroendocrine Cancer Foundation NET-Research-Foundation
Neuroendocrine Cancer UK Minkhas mission
  • clock 5 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education
NET CONNECT
Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
eks
EKS / On-demand webinar
Oncology 
ESMO 2025: Gastric and gastroesophageal cancer insights for clinical practice

On-demand materials from an Experts Knowledge Share event

Experts
Dr Elizabeth Smyth, Prof. Aziz Zaanan, Prof. Markus Moehler
Endorsed by
ESDO
Digestive Cancers Europe
ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 67 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education
GI CONNECT PRECISION ONCOLOGY CONNECT GI NURSES CONNECT
Educational programme supported by an Independent Educational Grant from Amgen.
Explore all programmes